Deals19 Jan 2024, 01:25 pm
Zydus Lifesciences Ltd. partners with Synthon for exclusive licensing and supply agreement for Palbociclib Tablets in the US market
AI Summary
Zydus Lifesciences Ltd. has entered into an exclusive licensing and supply agreement with Synthon BV for Palbociclib Tablets (generic version of IBRANCE®) for the US market. Under the agreement, Synthon will be responsible for obtaining US regulatory approval and manufacturing, while Zydus will be responsible for commercialization. The partnership aims to bring access to an important drug product for patients in the US.,
Key Highlights
- Zydus partners with Synthon for exclusive licensing and supply agreement for Palbociclib Tablets in the US market
- First to market opportunity for Zydus in the US
- Important drug product for patients in the US
- Partnership to bring high-quality generic version of IBRANCE® to the market